From Stagnation To Surge: Gilead Sciences Is Entering Its Next Growth Wave

Gilead Sciences (GILD) has rallied 53% including dividends since the prior bullish assessment, now approaching its 2015 peak, driven by solid Q2/25 results that beat revenue and EPS expectations, with HIV product sales up 7% to $5.1 billion. The company raised its FY25 guidance for product sales and EPS, anticipating improving operating margins and long-term growth from its HIV portfolio, notably the recently approved Yeztugo (Lencapavir) with significant peak sales potential, and a robust pipeline. Despite recent gains, the article asserts GILD remains undervalued, citing a 15.88x price-to-free cash flow multiple, a discounted cash flow intrinsic value of $142.06, a new $6 billion share buyback program, and a bullish technical outlook with a $190 target.

Analysis

Gilead Sciences (GILD) has demonstrated a significant shift in momentum, breaking out of a multi-year trading range with a 53% increase in value, including dividends, over the past year. The company's Q2 2025 results underpin this strength, with beats on both revenue and EPS expectations. While headline revenue growth was a modest 1.8% year-over-year to $7.08 billion, a more telling metric is the 3.5% growth when excluding the declining sales of Veklury. The core HIV franchise remains robust, with sales increasing 7% to $5.1 billion, driven by flagship product Biktarvy, which alone accounts for half of the company's revenue and grew 8.9%. Despite a 6.4% decline in GAAP operating income, this was attributed to productive long-term investments in R&D and a one-time $190 million impairment charge. Reflecting underlying strength, the company raised its full-year 2025 guidance for both product sales (now $28.3-$28.7 billion) and diluted EPS (now $5.85-$6.15). The long-term outlook is bolstered by the recent US approval and launch of Yeztugo (Lencapavir), a potential market-changing HIV drug with peak sales estimates ranging from $4.5 billion to $8 billion. This new catalyst, combined with Biktarvy's patent protection until the early 2030s, provides a clear growth runway. While a new $6 billion share repurchase program has been authorized, it is primarily intended to offset dilution rather than aggressively reduce share count. From a valuation perspective, the stock trades at 15.88x price-to-free-cash-flow, above its 15-year average, but a discounted cash flow analysis suggests a higher intrinsic value of $142.06, indicating further upside potential.

Key Decisions for Investors

• Despite the recent 53% rally, the combination of raised FY25 guidance, strong core HIV franchise performance, and a new growth catalyst in Yeztugo supports a continued bullish long-term outlook.
• Investors should monitor the initial commercial uptake and sales trajectory of Yeztugo, as its projected peak sales of $4.5-$8 billion are central to the thesis of accelerating long-term growth.
• While the stock is no longer considered a deep-value play, the provided DCF-based intrinsic value of $142.06 suggests further capital appreciation is possible, justifying a hold or accumulation strategy for those with a multi-year horizon.
• Note that the new $6 billion share buyback is a supportive factor but is expected to primarily offset dilution, meaning investors should not model aggressive EPS accretion from repurchases alone.